Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-glucosidase 2 (GBA2) is a non-lysosomal enzyme that catalyzes the hydrolysis of glucosylceramide, a membrane lipid, into glucose and ceramide. This reaction is crucial for the metabolism of glycosphingolipids on the cytoplasmic face of cellular membranes. Mutations in the GBA2 gene are associated with genetic neurological disorders such as hereditary spastic paraplegia and cerebellar ataxia, highlighting its importance in nervous system function. It belongs to the Glycoside hydrolase family GH116, distinct from lysosomal glucocerebrosidase/GBA which belongs to GH30.
Hydrolyzes glucosylceramide into glucose and ceramide using a double-displacement mechanism.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-glucosidase 2 (GBA2).